Rockwell Medical, Inc.

What they do

Rockwell develops, manufactures, commercializes, and distributes hemodialysis concentrates, dialysates, and related ancillary products for end-stage kidney disease patients. It operates one reportable segment, the hemodialysis market, and serves approximately 300 customers, including all five leading U.S. dialysis providers. Manufacturing occurs at facilities in Michigan and Texas, with dry acid concentrate mixers made in Iowa; the South Carolina facility ceased manufacturing in Q3 2025. Its products are FDA-regulated, ISO 13485 certified, and produced under cGMP and AAMI standards.

Revenue drivers

• Hemodialysis concentrates and ancillary products — Dialysate concentrates and other ancillary products accounted for 100% of revenue for the six months ended June 30, 2026, with approximately 85% of sales to distributors and customers for U.S. use.
• U.S. dialysis providers — The company serves roughly 300 customers, including all five leading U.S. dialysis providers such as Fresenius Medical Care North America and DaVita Inc.; most individual customer concentrations are under 10% of sales.
• New customer additions, particularly Western U.S. — Management attributed Q2 2026 net sales growth primarily to additional sales to new customers in the Western United States and greater purchasing from existing customers.

Recent performance

Q2 2026 net sales were $17.8 million, an 11% increase over $16.1 million in Q2 2025, driven by new Western U.S. customers and higher purchasing from existing customers. Gross profit rose 30% to $3.2 million, and gross margin expanded to 18% from 16% on lower manufacturing costs and higher volume. Net loss improved to $1.2 million from $1.5 million a year earlier, and adjusted EBITDA was negative $0.2 million, in line with Q2 2025. The company generated $2.1 million of cash flow from operations in Q2 2026, and reported cash, cash equivalents, and investments available-for-sale of $24.8 million at June 30, 2026.

Strategy

Rockwell's commercial team is focused on expanding revenue within its current customer base and adding new accounts to grow market share in hemodialysis concentrates. Management emphasizes long-term customer partnerships, appropriate pricing, and high-quality product delivery to dialysis providers. In 2025 the company added a 510(k)-approved single-use bicarbonate cartridge, signed a multi-year product purchase agreement with Innovative Renal Care, and added 30 new customers in the Western U.S. It also concluded manufacturing at its South Carolina facility in Q3 2025 to streamline operations and improve efficiency. In May 2026 the company announced a three-year product purchase agreement with Heritage Dialysis.

Risks

• Competition from larger rivals — Rockwell faces competition in the concentrates market from large competitors with substantially greater resources.
• Customer concentration and retention — The business depends on retaining major customers and distributors, including all five leading U.S. dialysis providers, and on negotiating favorable agreements.
• Input cost and margin pressure — Increases in raw material, labor, fuel, or other input costs could hurt results if the company cannot pass them through to customers.
• Regulatory and reimbursement risk — The business is highly regulated, and changes in FDA requirements or insurance and government reimbursement could materially affect operations.

Outlook

Management said it is on track to achieve full-year 2026 guidance with emphasis on top-line growth, improving gross margins, and positive cash flow. CEO Mark Strobeck stated the company is focused on executing its growth strategy, expanding profitability, and generating positive cash flow in the second half of the year. The company reported a solid cash position ($24.8 million at June 30, 2026) and cited a growing customer base and improving margins.